证券代码：002513 证券简称：蓝丰生化 公告编号：2025-068 江苏蓝丰生物化工股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、对外担保情况概述 江苏蓝丰生物化工股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、2025 年 5 月 22 日召开公司第七届董事会第二十三次会议、2024 年年度 股东大会，审议通过了《关于预计 2025 年度为子公司提供对外担保额度的议 案》。为满足日常经营和业务发展的资金需要，公司及子公司拟为合并范围内 子公司融资事宜提供总额不超过人民币 30 亿元的担保，部分子公司资产负债率 超过 70%。担保范围包括但不限于申请综合授信、贷款、承兑汇票、信用证、 保理、保函、融资租赁、供应链融资等融资业务。具体内容详见公司于 2025 年 4 月 29 日刊登在《上海证券报》、《证券时报》、《中国证券报》和巨潮资讯 网（www.cninfo.com.cn）上的《关于预计 2025 年度为子公司提供对外担保额 度的公告》（公告编号：2025-015）。 二、担 ...

Core Viewpoint - Bluefeng Biochemical experienced a 5.43% increase in stock price, reaching 8.35 CNY per share, with a trading volume of 322 million CNY and a turnover rate of 15.13%, resulting in a total market capitalization of 2.969 billion CNY [1] Company Overview - Jiangsu Bluefeng Biochemical Co., Ltd. was established on October 11, 1990, and listed on December 3, 2010. The company is located at No. 2 Ningxia Road, Xinyi Economic Development Zone, Jiangsu [1] - The main business activities include the production and sales of pesticide raw materials and formulations, fine chemical intermediates, and pharmaceutical manufacturing [1] - The revenue composition of the main business is as follows: battery cells 43.84%, modules 31.70%, pesticide raw materials and formulations 17.20%, sulfuric acid 4.09%, other photovoltaic businesses 1.85%, and other agricultural chemical products 1.32% [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Guotai Fund has a significant position in Bluefeng Biochemical. The Guotai Juzi Quantitative Stock Selection Mixed Fund A (023386) held 8,400 shares in the third quarter, accounting for 0.87% of the fund's net value, making it the largest holding [2] - The fund has an estimated floating profit of approximately 3,612 CNY as of the report date [2] - The Guotai Juzi Quantitative Stock Selection Mixed Fund A was established on September 2, 2025, with a latest scale of 9.0448 million CNY and a cumulative return of 5.87% since inception [2] - The fund manager, Wu Kefan, has been in position for 2 years and 152 days, managing total assets of 2.092 billion CNY, with the best fund return during his tenure being 72.85% and the worst being -17.64% [2]

Group 1 - The company, Lanfeng Biochemical, responded to investor inquiries on October 29 regarding the number of shareholders, indicating that detailed information can be found in the company's periodic reports [2]

Core Viewpoint - The company, Lanfeng Biochemical, addressed investor inquiries on October 29, stating that its operational status can be found in the periodic reports disclosed by the company [2] Summary by Relevant Sections - **Company Operations** - Lanfeng Biochemical confirmed that detailed information regarding its operational performance is available in the periodic reports it has released [2]

Group 1 - The company, Jiangsu Lanfeng Biological Chemical Co., Ltd., has completed the registration change and received a new business license following a reduction in registered capital and amendments to its articles of association [2][3]. - The registered capital after the change is 355.563978 million yuan [2]. - The company operates in various sectors including the production and sale of pesticides, chemical products, and renewable energy technologies [2]. Group 2 - The company held its seventh board meeting and the first extraordinary shareholders' meeting in 2025 to approve the capital reduction and related amendments [2]. - The new business license includes updated information such as the unified social credit code and the legal representative [2]. - The company is involved in the import of raw materials and machinery necessary for its production and research activities [2].

Core Viewpoint - Recently, the company completed the registration capital change and related business registration changes, obtaining a new business license from the Xuzhou Municipal Administration of Government Services [1] Group 1 - The company is Bluefeng Biochemical (002513) [1] - The announcement was made on the evening of October 27 [1] - The company has updated its articles of association as part of the registration process [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-067 江苏蓝丰生物化工股份有限公司 近日，公司完成了注册资本变更及《公司章程》备案相关工商登记变更手续， 并取得了徐州市政务服务管理办公室换发的《营业执照》，变更后营业执照内容 如下： 名称：江苏蓝丰生物化工股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、基本情况 类型：股份有限公司（上市） 二、完成工商变更登记情况 住所：江苏新沂经济开发区宁夏路 2 号 法定代表人：李质磊 江苏蓝丰生物化工股份有限公司（以下简称"公司"）分别于 2025 年 7 月 28 日、2025 年 8 月 15 日召开第七届董事会第二十四次会议、2025 年第一次临 时股东会审议通过了《关于减少注册资本、修订<公司章程>并办理工商登记的议 案 》 。 具 体 内 容 详 见 公 司 刊 登 在 指 定 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上 的《关于减少注册资本、修订< ...

Core Viewpoint - The stock of Jiangsu Lanfeng Bio-chemical Co., Ltd. has shown significant growth this year, with a year-to-date increase of 97.32%, indicating strong market interest and performance in the agricultural chemicals sector [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.83 billion yuan, representing a year-on-year growth of 28.26% [2]. - The net profit attributable to shareholders was -77.18 million yuan, showing a year-on-year increase of 58.29% despite being negative [2]. Stock Market Activity - As of October 27, the stock price reached 8.84 yuan per share, with a trading volume of 319 million yuan and a turnover rate of 13.96% [1]. - The stock has appeared on the daily trading leaderboard 15 times this year, with the most recent appearance on October 23, where it recorded a net buy of -50.62 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders increased to 41,700, a rise of 48.71% from the previous period, while the average circulating shares per person decreased by 32.41% to 6,360 shares [2]. Business Segments - The company's main business segments include battery cells (43.84%), components (31.70%), pesticide raw materials and formulations (17.20%), and sulfur (4.09%) [2].

Core Viewpoint - Bluefeng Biochemical (002513.SZ) reported a revenue of 1.83 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 28.26%. However, the company recorded a net loss attributable to shareholders of 77.18 million yuan, with a net loss of 79.47 million yuan after excluding non-recurring gains and losses [1] Financial Performance - The company achieved an operating income of 1.83 billion yuan in the first three quarters of 2025 [1] - Year-on-year revenue growth was reported at 28.26% [1] - The net loss attributable to shareholders was 77.18 million yuan [1] - The net loss after excluding non-recurring gains and losses was 79.47 million yuan [1]

Group 1 - The core point of the article is that Lanfeng Biochemical (SZ 002513) held its 28th meeting of the 7th board of directors on October 24, 2025, via telecommunication, where it reviewed the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Lanfeng Biochemical's revenue composition was 77.39% from photovoltaic products and 22.61% from pesticides [1] - As of the time of reporting, Lanfeng Biochemical had a market capitalization of 3.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]